Results 51 to 60 of about 6,307 (191)

Haemostatic changes and bleeding with anti‐IL‐6 directed therapy in autoimmune diseases

British Journal of Pharmacology, Volume 183, Issue 15, Page 4111-4125, August 2026.
Abstract Anti‐IL‐6 directed therapy, especially tocilizumab (TCZ), is widely used for the treatment of autoimmune diseases such as rheumatoid arthritis, giant cell arteritis and systemic juvenile idiopathic arthritis. Next to being a master regulator of inflammation, IL‐6 also is an important regulator of haemostasis. Although generally well tolerated,
Charlotte D. C. C. van der Heijden, Loes C. Oskam, Lenny van Bon, Chantal P. Rovers   +3 more
wiley   +1 more source

Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database

Frontiers in Pharmacology
BackgroundBiktarvy, a second-generation integrase strand-transfer inhibitor, is approved for treating human immunodeficiency virus (HIV) in patients with no known resistance to its components.
Xinmei Pan, Qingqing Tian, Qian Wang, Linli Xie, Jiangchuan Xie   +4 more
doaj   +1 more source

Real-world FAERS safety analysis of Pralsetinib

Scientific Reports
The FDA has approved pralsetinib as a chemotherapeutic drug for the treatment of individuals with cancers such as medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and non-small cell lung cancer (NSCLC). However, there is a lack of information on drug safety in large cohorts.
Zhang, Dongdong, Sun, Yixin, Cai, Ying, Zeng, Peiji, Wang, Yue, Cai, Ming, Cai, Chengfu   +6 more
openaire   +3 more sources

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6767-6775, August 2026.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Response to Xing et al.: post-marketing safety concerns with Lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database

Alzheimer’s Research & Therapy
A recent paper published a lecanemab analysis with data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database.
Michael Irizarry, Ilona Surick, Ari Michael, Lynn D. Kramer   +3 more
doaj   +1 more source

RxNorm for drug name normalization: a case study of prescription opioids in the FDA adverse events reporting system

Frontiers in Bioinformatics
Numerous studies have been conducted on the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS) database to assess post-marketing reporting rates for drug safety review and risk assessment. However, the drug names in the adverse
Huyen Le, Ru Chen, Stephen Harris, Hong Fang, Beverly Lyn-Cook, Huixiao Hong, Weigong Ge, Paul Rogers, Weida Tong, Wen Zou   +9 more
doaj   +1 more source

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6482-6508, August 2026.
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan, Leon E. Cosler, Michael R. Gionfriddo, Emily E. Leppien, Eleanor J. Sommers, Mia E. Lussier   +5 more
wiley   +1 more source

Expanding on Abraxane Safety: Temporal Insights and Future Directions for Adverse Event Analysis [Letter]

International Journal of Nanomedicine
Fangcai Yang,1 Wukun Ge2 1Department of Clinical Nutrition, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of China; 2Department of Clinical Pharmacy, Ninghai First Hospital, Ningbo, Zhejiang, 315600, People’s Republic of
Yang F, Ge W
doaj  

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Kayla M. Teopiz, Angela T. H. Kwan, Joshua D. Rosenblat, Rodrigo B. Mansur, Hayun Choi, Roger S. McIntyre   +9 more
wiley   +1 more source

A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology
ObjectiveOmadacycline is a newly launched drug of tetracycline. Therefore, it is necessary to comprehensive evaluate reports on the safety of omadacycline in large, real-world populations.
Xueping Shi, Chen Wang, Xiang Liu, Li Zou, Pei Guo   +4 more
doaj   +1 more source